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Abstract
AIM: To assess tumour regression grade (TRG) and 
lymph node downstaging to help define patients who 
benefit from neoadjuvant chemotherapy.
METHODS: Two hundred and eighteen consecutive 
patients with adenocarcinoma of the esophagus or gas-
tro-esophageal junction treated with surgery alone or 
neoadjuvant chemotherapy and surgery between 2005 
and 2011 at a single institution were reviewed. Triplet 
neoadjuvant chemotherapy consisting of platinum, fluo-
ropyrimidine and anthracycline was considered for oper-
able patients (World Health Organization performance 
status ≤ 2) with clinical stage T2-4 N0-1. Response to 
neoadjuvant chemotherapy (NAC) was assessed using 
TRG, as described by Mandard et al . In addition lymph 
node downstaging was also assessed. Lymph node 
downstaging was defined by cN1 at diagnosis: assessed 
radiologically (computed tomography, positron emission 
tomography, endoscopic ultrasonography), then patho-
logically recorded as N0 after surgery; ypN0 if NAC 
given prior to surgery, or pN0 if surgery alone. Patients 
were followed up for 5 years post surgery. Recurrence 
was defined radiologically, with or without pathological 
confirmation. An association was examined between 
t TRG and lymph node downstaging with disease free 
survival (DFS) and a comprehensive range of clinico-
pathological characteristics. 
RESULTS: Two hundred and eighteen patients under-
went esophageal resection during the study interval with 
a mean follow up of 3 years (median follow up: 2.552, 
95%CI: 2.022-3.081). There was a 1.8% (n = 4) inpa-
tient mortality rate. One hundred and thirty-six (62.4%) 
patients received NAC, with 74.3% (n = 101) of patients 
demonstrating some signs of pathological tumour re-
gression (TRG 1-4) and 5.9% (n = 8) having a complete 
pathological response. Forty four point one percent (n 
= 60) had downstaging of their nodal disease (cN1 to 
ypN0), compared to only 15.9% (n  = 13) that under-
went surgery alone (pre-operatively overstaged: cN1 to 
pN0), (P  < 0.0001). Response to NAC was associated 
with significantly increased DFS (mean DFS; TRG 1-2: 5.1 
years, 95%CI: 4.6-5.6 vs  TRG 3-5: 2.8 years, 95%CI: 
2.2-3.3, P  < 0.0001). Nodal down-staging conferred 
a significant DFS advantage for those patients with a 
poor primary tumour response to NAC (median DFS; 
TRG 3-5 and nodal down-staging: 5.533 years, 95%CI: 
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3.558-7.531 vs  TRG 3-5 and no nodal down-staging: 
1.114 years, 95%CI: 0.961-1.267, P  < 0.0001).
CONCLUSION: Response to NAC in the primary tu-
mour and in the lymph nodes are both independently 
associated with improved DFS.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Predictive markers of benefit from neoadju-
vant chemotherapy (NAC) in esophageal adenocarci-
noma are urgently required to provide a “personalised 
medicine” approach: directing treatment to those most 
likely to benefit. Before prospective studies can be initi-
ated, retrospective series need to be interrogated to 
identify likely candidate markers of a positive response. 
In defining a positive response attention needs to be 
given to both response in the primary tumour and in 
the lymph nodes, as a previously unidentified group of 
patients who appear to have a poor tumoural response 
to NAC (tumour regression grade 3-5) do benefit from 
combination therapy by nodal downstaging.
Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, 
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INTRODUCTION
Neoadjuvant therapy followed by surgery is established as 
the gold standard in the management of  patients with lo-
cally advanced adenocarcinoma of  the esophagus/esopha-
gogastric junction. In the United Kingdom neoadjuvant 
chemotherapy (NAC) in conjunction with transthoracic 
esophagogastrectomy is the current standard of  care for 
these patients[1]. The potential benefits of  neoadjuvant 
therapy include: downstaging of  the primary tumour[2] 
and lymph nodes[3], an increase in the resectability of  the 
tumour[4], elimination of  micrometastases[5] and improved 
survival[6]. A recently suggested advantage of  neoadjuvant 
therapy and early assessment of  response is the potential 
for assessing in vivo the chemosensitivity of  the tumour and 
so providing information to tailor multimodal therapy[7]. 
Both NAC and surgery are associated with considerable 
morbidity and mortality[8] and evidence remains inconsistent 
for the survival benefit for patients who undergo NAC[4,8,9]. 
The most recent meta-analysis to compare NAC vs surgery 
alone in 2062 patients suggests a 5.1% survival advantage at 
2 years for patients treated with NAC for adenocarcinoma[6]. 
Patients who have a significant pathological response to 
neoadjuvant therapy have consistently been shown to have 
improved survival when compared to patients who have 
not had a significant response[10-13]. For those patients who 
do not have a significant pathological response, the conse-
quences of  delay to surgery and the benefits of  neoadjuvant 
chemotherapy are not known. Furthermore, it is unclear 
which patients should be considered for tailored adjuvant 
systemic therapy or alternative neoadjuvant therapy.
The pathological response to chemotherapy is most 
widely assessed using Tumour Regression Grading 
(TRG)[1] as described by Mandard et al[14] although this 
has not gained universal acceptance[15]. This system is 
based on the amount of  residual tumour and the degree 
of  fibrosis at the primary tumour[14]. Other proposed 
pathological systems for measuring neoadjuvant treat-
ment response include complete pathological response[16], 
size of  residual tumour[17], number of  residual tumour 
cells[15,18], response classification system[19], size based 
pathological response[17] and downstaging of  cT and cN 
stage[10]. These grading systems have predominately been 
developed following chemoradiotherapy with hetero-
geneous histology with few studies assessing their util-
ity following chemotherapy in patients with esophageal 
adenocarcinoma[2,20-23]. A number of  clinically important 
questions could be addressed by a robust and universally 
accepted measure of  response to neoadjuvant treatment 
including: the ability to accurately predict an individual pa-
tient’s tumour response to preoperative therapy leading to 
non-responders proceeding directly to surgery or being 
considered for alternative neoadjuvant regimes; assess-
ment of  new neoadjuvant regimes, and identification of  
patients who are likely to benefit from adjuvant therapy.
We have therefore assessed pathological response to 
neoadjuvant chemotherapy by assessing the tumour re-
sponse as well as the response in the lymph nodes in a large 
contemporary cohort of  patients with esophagogastric ad-
enocarcinoma managed with neoadjuvant platinum based 
triplet chemotherapy, and describe their associations with 
short- and long-term outcomes. In addition we suggest 
combining both local tumour and nodal responses to NAC.
MATERIALS AND METHODS 
Patients
For this retrospective study, a prospectively collected da-
tabase of  consecutive patients undergoing esophagogas-
tric resection treated at University Hospital Southampton 
National Health Service Foundation Trust (UHSFT) 
between January 2005 and December 2011 was reviewed. 
All patients were discussed at a specialist multidisciplinary 
team meeting (MDT). Standard staging investigations 
included endoscopic ultrasonography, high-resolution 
computed tomography, integrated fluorodeoxyglucose 
positron emission tomography/computed tomography 
(PET-CT) and staging laparoscopy, where indicated and 
were uniformly applied during the study interval. Patients 
considered suitable for potential surgical resection with 
tumours staged as T2N0M0 or above were considered 
for neoadjuvant chemotherapy. 
Neoadjuvant chemotherapy consisted of  three 21 d 
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cycles of  anthracycline, platinum and fluoropyrimidine: 
ECF (epirubicin 50 mg/m2, cisplatin 60 mg/m2, both intra-
venously on 1 d and protracted venous infusion 5-FU 200 
mg/m2 per day) or ECX (epirubicin 50 mg/m2, cisplatin 
60 mg/m2, both intravenously on 1 d and capecitabine 625 
mg/m2 orally twice daily for 21 d) or EOX (epirubicin 50 
mg/m2 iv bolus and oxaliplatin 130 mg/m2 iv infusion over 2 
h on 1 d, capecitabine 625 mg/m2 orally twice daily for 21 d).
Surgery was performed at UHSFT after initial staging 
or 4-6 wk following neoadjuvant chemotherapy. A repeat 
CT scan was performed, prior to surgery, for those who 
received chemotherapy to assess their response to che-
motherapy and disease operability. Types of  esophago-
gastrectomies included Ivor Lewis, left thoracoabdominal 
with or without cervical anastomosis and transhiatal 
esophagogastrectomy or minimally invasive esophago-
gastrectomy (MIO) either 2 stage (MIO-2) or 3 stage 
(MIO-3) in accordance with recommendations arising 
from the consensus statement from the Association of  
Upper Gastrointestinal Surgeons and the Association of  
Laparoscopic Surgeons for introduction of  MIO[24].
Data recorded included demographics, tumour char-
acteristics, resection type, estimated blood loss (calculated 
from suction bottles and weighed swabs) and histopatho-
logical analysis of  the surgical specimen. TNM-7 (Inter-
national Union Against Cancer TNM Classification 7th 
Edition) was used to report tumour stage after analysis 
of  pathology reports[25]. Pathological tumour clearance 
(“R”-status) was determined according the Royal College 
of  Pathologists’ guidance.
Postoperative complications were graded according 
to the Clavien-Dindo (CD) classification[26]. An AL was 
defined as a leak sufficient to cause symptoms and con-
firmed by radiology (contrast enhanced multi-detector 
CT scan with on-table oral contrast or water soluble con-
trast studies), endoscopy or during surgical exploration. 
All patients were cared for by a specialist esophagogas-
tric team who applied a similar perioperative regime to all 
patients. Patients were routinely followed-up for 5 years 
post surgery according to the following protocol: 2-4 wk 
post-discharge, 3 monthly for 1 year, 6 monthly for 2 years 
and yearly thereafter. Patients were also seen on an “as re-
quired” basis if  symptomatic. Recurrence of  disease during 
follow-up was defined as the first site or sites of  recurrence 
with radiological or pathological confirmation. For assess-
ment of  disease free survival (DFS), recurrence was defined 
as time from operation to development of  local, nodal (re-
gional) and distant metastasis (whichever occurred first).
Factors analysed
Pathological response to chemotherapy was assessed using 
the TRG system developed by Mandard et al[14] who scored 
regression based on the degree of  fibrosis and residual 
cancer cells (TRG 1-5)[14,27], see Table 1. All dissected lymph 
nodes were stained with hematoxylin and eosin and micro-
scopically analysed for metastatic disease. TRG was scored 
by specialist gastrointestinal pathologists; initially by one 
pathologist (Bateman AC) prior to its introduction by all 
pathologists as part of  routine pathological reporting.
Statistical analysis
Descriptive data are represented as median and range un-
less indicated with Kruskal-Wallis, Mann Whitney U, P 
and χ 2 test, which were used as appropriate for compari-
son. Kaplan-Meier, univariate and multivariate cox logistic 
regression modelling were used to assess the relationship 
between pathological response grading systems with DFS. 
All factors that showed statistical significance on univari-
ate analysis were entered to derive the final model. DFS 
curves of  the patients were plotted by using the Kaplan-
Meier method and analysed using the Log-rank test. 
Stratified analyses were performed based on receipt of  
neoadjuvant chemotherapy, nodal stage and response to 
chemotherapy. A P < 0.05 was considered statistically sig-
nificant for all tests. Statistical analysis was performed with 
SPSS® version 19 (SPSS, Chicago, Illinois, United States).
RESULTS
Study patients
A total of  218 patients underwent esophageal resection 
during the study interval with a mean follow up of  3 years 
(median follow up: 2.552, 95%CI: 2.022-3.081). There was 
a 1.8% (n = 4) inpatient mortality rate. Detailed patient 
characteristics and clinical and pathological outcomes are 
summarised in Table 2, grouped by treatment.
Patients who underwent surgery alone (n = 82; 
37.6%) were significantly older (P < 0.0001), had worse 
physiological status (ASA P = 0.005; performance status 
P = 0.001; O-POSSUM P < 0.0001) and lower preopera-
tive staged disease (cT stage P < 0.0001; cN stage P < 
0.0001) compared to patients that underwent multimodal 
therapy. 
One hundred thirty-six (62.4%) patients received mul-
timodal therapy, neoadjuvant chemotherapy and surgery, 
with 74.3% (n = 101) of  patients demonstrating some 
signs of  pathological tumour regression (TRG 1-4) with 
5.9% (n = 8) having a complete pathological response. 
Forty four point one percent (n = 60) had downstaging 
of  their nodal stage compared to only 15.9% (n = 13) 
whose lymph node status was cN1 on preoperative stag-
ing and pN0 following surgery alone (P < 0.0001). 
There were no statistically significant differences in 
postoperative pathological tumour stage (yp or pT, P = 
0.692); yp or pN P = 0.758), postoperative complications 
(CD maximum grade, P = 0.590) or completeness of  
resection (P = 0.772) in patients that underwent multi-
modal therapy vs surgery alone. 
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  Grade Definition
  TRG 1 No residual cancer
  TRG 2 Rare residual cancer cells
  TRG 3 Fibrosis outgrowing residual cancer
  TRG 4 Residual cancer outgrowing fibrosis
  TRG 5 Absence of regressive changes
Table 1  Tumour regression scoring according to Mandard 
et al [14]
TRG: Tumour Regression Grade.
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  Characteristic Surgery only 82 (37.6) Neoadjuvant chemotherapy and P  value
surgery 136 (62.4)
  Preoperative status
     Age (range)1 yr 74.32 (42.08-85.41) 63.76 (32.77-81.28) < 0.0001
     Sex ratio (M:F)1 68 (82.9):14 (17.1) 118 (86.8):18 (13.2)   0.439
     cT stage 1    17 (20.7)    0 (0.0) < 0.0001
2    30 (36.6)    16 (16.0)
3    34 (41.5)  114 (84.0)
4    1 (1.2)    6 (4.4)
     cN stage 0    36 (43.9)    19 (14.0) < 0.0001
1    46 (56.1)  117 (86.0)
     cM stage 0    80 (97.6)  134 (98.5)   0.613
1    1 (2.4)    2 (1.4)
     Performance status 0      8 (11.6)    35 (25.7)   0.001
1    51 (73.9)    96 (70.6)
2    10 (14.5)    5 (3.7)
     ASA 1    3 (3.7)  11 (8.1)   0.005
2    56 (68.3)  106 (78.5)
3 23 (28)    18 (13.3)
  O-POSSUM      18 (12-30)       16 (12-26) < 0.0001
     Tumour site Middle 1/3    1 (1.2)    1 (0.7)   0.418
Lower 1/3 32 (39)    57 (41.9)
GEJ-S1    19 (23.2)    23 (16.9)
GEJ-S2    18 (22.0)    34 (25.0)
GEJ-S3    12 (14.6)    20 (14.7)
  Operative outcomes
     Length of operation (min)1        255 (120-480)        261 (120-471)   0.409
     Blood loss (mL)1      300 (0-2200)      318 (0-3000)   0.429
     Clavien Dindo Max 0    26 (31.7)    53 (39.3) 0.59
1    5 (6.1)    8 (5.9)
2    35 (42.7)    40 (29.6)
3    6 (7.3)    17 (12.6)
4    6 (7.3)    17 (12.6)
5    4 (4.9) 0 (0)
     Anastomotic leaks    8 (9.8)    9 (6.7)   0.413
  Pathological outcomes
     pT or ypT 0    3 (3.6)    8 (5.9)   0.692
1 23 (28)    23 (16.9)
2    17 (20.7) 34 (25)
3    34 (41.5)    66 (48.5)
4    5 (6.1)    5 (3.7)
     pN or ypN 0    40 (48.8)    73 (53.7)   0.758
1    20 (24.4)    21 (15.4)
2    11 (13.4)    25 (18.4)
3    11 (13.4)    17 (12.5)
     pM or ypM 0   82 (100) 136 (100) 1.00
     Tumour regression grade 1 -    8 (5.8) n/a
2 -    28 (20.6)
3 -    20 (14.7)
4 -    45 (33.1)
5 -    35 (25.7)
     Nodal downstaged (cN1 to p or ypN1)    13 (15.9)    60 (44.1) < 0.0001
     Positive nodes1      1 (0-21)      0 (0-24)   0.789
     Nodal yield1    18 (4-49)    18 (3-53)   0.242
     Resection clearance R0    65 (79.3)  110 (80.9)   0.772
     Vascular invasion    24 (29.3)    41 (30.1)   0.891
     Lymphatic invasion   9 (11)    22 (16.2) 0.28
     Perineural invasion    8 (9.8)    20 (14.7)   0.291
     Maximum tumour diameter (mm)1    25 (0-90)      25 (0-155)  0.998
     Morphology Ulcer 48 (60)    96 (74.4)   0.029
Polypoid    22 (27.5)    23 (17.8)
Fungating    2 (2.5)    3 (2.3)
Diffuse infiltrating   8 (10)    7 (5.4)
     Grade G1    6 (7.3)    16 (11.8)   0.669
G2    30 (36.6)    37 (27.2)
G3    46 (56.1)    82 (60.3)
G4 0 (0)    1 (0.7)
     Sites of recurrence Local    3 (3.7)    8 (5.9)   0.461
Table 2  Clinical and pathological characteristics of the 218 patients operated on for esophageal and gastro-esophageal 
adenocarcinoma, according to treatment  n (%)
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The relationship of tumour regression grade and 
clinicopathological characteristics
The relationship between patient and tumour character-
istics and response to neoadjuvant chemotherapy, as de-
fined by tumour regression grade, are presented in Table 3.
Of the 136 patients that underwent NAC, 36 (26.5%) 
patients had a significant pathological response (TRG 1-2; 
responders) compared to 100 (73.5%) patients with no sig-
nificant pathological response (TRG 3-5; non-responders). 
Responders and non-responders had similar preoperative 
clinical features (age, sex and physiological status) and clini-
cal stage of  disease (cT stage, P = 0.396; cN stage, P = 0.987; 
cM stage, P = 0.456), yet responders had markedly reduced 
ypT stage (P < 0.0001), maximal pathological tumour di-
ameter (P < 0.0001), and ypN stage (P < 0.0001) and were 
more likely to have their nodal stage downstaged (P < 
0.0001) compared to non-responders (Table 3). In addition, 
responders had tumours that were more likely to be ulcers 
(P = 0.003), showing less vascular (P = 0.004), and peri-
neural invasion (P = 0.072) compared to non-responders. 
Complete resection (R0) was achieved in 97.2% (n = 35) of  
responders compared with 75% (n = 75) of  non-responders 
(P = 0.04). There was no significant difference in postopera-
tive complications as classified by the Clavien Dindo system, 
nodal yield, blood loss or operative time between groups.
The relationship of TRG and lymph node downstaging 
with DFS
There was a significant difference in survival between 
responders compared to non-responders, shown in 
Figure 1A [mean DFS; TRG 1-2: 5.064 years, 95%CI: 
4.560-5.569 (median DFS: not reached) vs TRG 3-5: 2.759 
years, 95%CI: 2.193-3.325 (median DFS: 1.613, 95%CI: 
0.834-2.39), P < 0.0001].
There was no statistically significant difference in 
survival between patients graded as TRG 1 compared to 
TRG 2 [mean DFS; TRG-1: 5.021, 95%CI: 4.069-5.973 vs 
TRG-2: 4.983, 95%CI: 4.069-5.973, P < 0.0001 (median 
DFS’s: not reached)].
Patients with lymph node downstaging following NAC 
had improved DFS vs patients without downstaging, Fig-
ure 1B [median DFS; lymph node (LN) downstaged: 5.316 
years, 95%CI: 4.504-6.127 (median DFS: 5.544) vs LN not 
downstaged: 2.118 years, 95%CI: 1.594-2.643 (median 
DFS: 1.210, 95%CI: 1.026-1.394), P < 0.0001].
Univariate and multivariate analysis for predicting DFS 
following neoadjuvant chemotherapy
Univariate and multivariate analysis confirmed known 
predictors of  DFS in esophageal adenocarcinoma (OAC) 
that are detailed in Table 4. Factors that retained signifi-
cance for the prediction of  worse DFS on multivariate 
analysis were: vascular invasion (HR = 1.929, 95%CI: 
1.034-3.6, P = 0.039), perineural invasion (HR = 2.766, 
95%CI: 1.444-5.3, P = 0.002), no significant response to 
NAC (HR = 6.315, 95%CI: 1.261-31.616, P = 0.025) and 
the absence of  lymph node downstaging (HR = 6.161, 
95%CI: 1.683-22.554, P = 0.006).
The relationship of lymph node downstaging and status 
with clinicopathological characteristics and DFS
Patients with no pathological lymph node involvement 
were compared (pN0 vs ypN0), grouped as those who had 
surgery alone (pN0) vs multimodal therapy (ypN0), with 
detailed clinical and pathological characteristics presented 
in Table 5 and DFS shown in Figure 1C.
For patients with no evidence of  pathological lymph 
node involvement increased pre-operative clinical stage 
(cT stage, P < 0.0001; cN stage, P < 0.0001) of  disease 
and increased nodal downstaging (NAC 83.6% vs surgery 
alone 37.5%, P < 0.0001) was observed in patients who 
received multimodal therapy vs surgery alone despite 
pathological stage being similar (yp or pT stage, P = 0.224; 
yp or pN stage, P = 1.00).
Patients who underwent surgery alone (pN0) had in-
creased DFS compared to patients who underwent NAC 
and surgery (ypN0) (mean DFS; pN0: 6.285 years, 95%CI: 
5.647-6.923 vs ypN0: 5.102 years, 95%CI: 4.314-5.891 
(median DFS’s: not reached, P = 0.042).
Evaluation of combined local tumour response grade 
and lymph node downstaging
Eighty-three point three percent of  responders’ addition-
ally demonstrated downstaging of  their regional lymph 
nodes compared to only 30% of  non-responders, spread 
across TRG 3-5, Figure 2.
The presence of  lymph node downstaging in apparent 
non-responders was associated with significantly improved 
DFS (median DFS; TRG 3-5 and nodal down-staging: 
5.544, 95%CI: 3.558-7.531 vs TRG 3-5 and LN not down-
staged: 1.114, 95%CI: 0.961-1.267, P < 0.0001), Figure 3.
DISCUSSION
Neoadjuvant treatment for esophageal cancer is associ-
ated with increased survival. However, it is clear that not 
all patients (and their tumours) respond to neoadjuvant 
therapy in the same way. It is likely that improved out-
comes will be observed by the tailoring of  neoadjuvant 
and adjuvant therapy based on patient stratification ac-
cording to tumour response. 
In this study we have analysed a consecutive cohort 
of  patients with esophageal adenocarcinoma (OAC) 
undergoing treatment with curative intent to assess the 
primary tumour and regional lymph node response to 
NAC. We have described three main findings: firstly, we 
Values in parentheses are percentages unless indicated. 1Values in parentheses are range. ASA: American society of anesthesiologists classification; 
O-POSSUM: Oesophagogastric surgery-physiological and operative severity score for the enumeration of mortality and morbidity; GEJ-S1-3: Gastro-
esophageal junction-Siewert type 1-3.
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Nodal    5 (6.1)    14 (10.4)   0.281
Distant    18 (22.0)    44 (32.6)   0.093
9287 December 28, 2013|Volume 19|Issue 48|WJG|www.wjgnet.com
TRG 1-2 36 (26.5) TRG 3-5 100 (73.5) P  value
  Preoperative status
     Age (range) yr1 65.27 (26.99-76.04) 63.51 (32.77-81.28)   0.410
     Sex ratio (M:F)1 32 (88.9):4 (11.1) 86 (86):14 (14)   0.662
     cT stage 1 0 (0) 0 (0)   0.396
2    2 (5.6) 14 (14)
3    33 (91.7) 81 (81)
4    1 (2.8) 5 (5)
     cN stage 0      5 (13.9) 14 (14)   0.987
1    31 (86.1) 86 (86)
     cM stage 0    35 (97.1) 99 (99)   0.456
1    1 (2.8) 1 (1)
     Performance status 0    12 (33.3) 23 (23)   0.225
1    23 (63.9) 73 (73)
2    1 (2.8)    4 (4.0)
     ASA 1    2 (5.6)    9 (9.1)   0.408
2    32 (88.9)    74 (74.7)
3    2 (5.6)    16 (16.2)
     O-POSSUM      15 (12-23)      16 (12-26)   0.476
     Tumour site Middle 1/3    1 (2.8) 0 (0)   0.738
Lower 1/3    15 (41.7) 42 (42)
GEJ-S1      7 (19.4) 16 (16)
GEJ-S2    9 (25) 25 (25)
GEJ-S3      4 (11.1) 16 (16)
  Operative outcomes
     Length of operation (min)1        262 (163-427)        260 (120-471)   0.513
     Blood loss (mL)1      300 (0-3000)      325 (0-1700)   0.673
     Clavien Dindo Max 0    14 (38.9)    39 (39.4)   0.531
1    2 (5.6)    6 (6.1)
2    14 (38.9)    26 (26.3)
3      4 (11.1)    13 (13.1)
4    2 (5.6)    15 (15.2)
5 0 (0) 0 (0)
     Anastomotic leaks    1 (2.8)    8 (8.1)   0.276
  Pathological outcomes
     yPT 0      8 (22.2) 0 (0) < 0.0001
1    11 (30.6) 12 (12)
2   9 (25) 25 (25)
3      8 (22.2) 58 (58)
4 0 (0) 5 (5)
     yPN 0    34 (94.4) 39 (39) < 0.0001
1 0 (0) 21 (21)
2    2 (5.6) 23 (23)
3 0 (0) 17 (17)
     yPM 0   36 (100) 100 (100)   0.579
     Nodal downstaged (cN1 to ypN0)    30 (83.3) 30 (30) < 0.0001
     Positive nodes1    0 (0-5)      1 (0-24) < 0.0001
     Nodal yield1    18 (4-25)    18 (3-53)   0.984
     Resection clearance R0    35 (97.2) 75 (75)   0.004
     Vascular invasion      4 (11.1) 37 (37)   0.004
     Lymphatic invasion      4 (11.1) 18 (18)   0.338
     Perineural invasion    2 (5.6) 18 (18)   0.072
     Maximum tumour diameter1 (mm)      15 (0-110)      30 (0-155) < 0.0001
     Morphology Ulcer    30 (93.8) 66 (68)   0.003
Polypoid    2 (6.3)    21 (21.6)
Fungating 0 (0)    3 (3.1)
Diffuse infiltrating 0 (0)    7 (7.2)
     Grade G1      8 (22.2) 8 (8)   0.104
G2   9 (25) 28 (28)
G3    19 (52.8) 63 (63)
G4 0 (0) 1 (1)
     Sites of recurrence Local 0 (0)    8 (8.1)   0.080
Nodal    1 (2.8)    13 (13.1)   0.082
Distant    2 (5.6)    42 (42.4) < 0.0001
Table 3  Clinical and pathological characteristics of the 136 patients treated with neoadjuvant chemotherapy for esophageal and gastro-
esophageal adenocarcinoma, classified as responders Tumour regression grade 1-2 or non-reponders tumour regression grade 3-5  n (%)
Values in parentheses are percentages unless indicated. 1Values in parentheses are range. TRG: Tumour Regression Grade; ASA:American Society of 
Anesthesiologists classification; O-POSSUM: Oesophagogastric surgery-physiological and operative severity score for the enumeration of mortality and morbidity; 
GEJ-S1-3: Gastro-esophageal junction-Siewert type 1-3.
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have confirmed that a significant pathological response as 
described by Mandard et al[14] is associated with improved 
DFS; Secondly we have confirmed that lymph node 
downstaging leads to improved DFS[10]; Thirdly, and most 
importantly, we describe that when tumour and nodal re-
sponse are combined, a group of  patients who previously 
would have been classified as non-responders to NAC 
actually have significantly increased DFS.
There is considerable debate regarding the role of  
tumour regression in OAC. Conflicting opinions are evi-
dent, for what represents a significant tumour response, 
even within the TRG grading system. In our study TRG-3 
tumours, despite representing tumours whose fibrosis out-
grows the residual tumour, clearly grouped with TRG-4 
and TRG-5 and not TRG-1 and TRG-2 tumours in terms 
of  DFS. This is in keeping with previous studies that have 
observed a significant increase in survival and/or metabol-
ic response on serial PET imaging for TRG groups 1 and 
2 compared to TRG groups 3 to 5[14,18,19,22,28,29]. In addition, 
we found there to be no significant difference in DFS be-
tween complete pathological responders (TRG-1) vs major 
responders (TRG-2) consistent with other studies[14,22]. As 
has been previously suggested this may reflect a type Ⅱ 
error due to insufficient sample size or the intensity of  
pathological sampling[22]. The observed increase in DFS in 
patients with a significant tumour response to NAC in this 
study may also reflect the significantly increased resectabil-
ity (R0 rate) of  the primary tumour. It may also reflect the 
selection of  tumours that are biologically more favourable 
as suggested by reduced vascular invasion (P = 0.004), tu-
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mour morphology (P = 0.003) and increased lymph node 
downstaging (P < 0.0001). 
In this study we confirmed the association between 
lymph node downstaging after NAC and improved 
DFS[10]. Bollschweiler et al[3] showed regression in lymph 
nodes, such as central fibrosis, to predict improved 
survival and response to chemoradiotherapy[3]. This 
would require additional pathological time and expertise 
whereas downstaging can be more simply assessed from 
the data available to the multidisciplinary team (MDT) 
after surgery, to assess a patient’s prognosis and potential 
for adjuvant therapies. The number of  positive lymph 
nodes is consistently the most important prognostic 
factor associated with survival[30]. However, the clinical 
significance of  downstaging is controversial due to the 
difficulties in evaluating preoperative status. This study 
has the advantage of  using contemporary and uniformly 
implemented clinical staging based on current United 
Kingdom practice. The comparison of  nodal stage based 
on pre-operative staging assessment (cN) and post-
operative pathology (pN) is open to the criticism that 
any downstaging simply reflects overdiagnosis of  lymph 
node metastases on preoperative staging. To address this 
point we assessed the survival of  patients with no posi-
tive lymph nodes in the pathological specimen, compar-
ing NAC with surgery alone (ypN0 vs pN0). We found 
that patients receiving NAC with ypN0 disease had 
reduced DFS across all sites of  recurrence compared to 
patients treated by surgery alone with pN0 disease. This 
reached statistical significance when overall DFS was as-
sessed (P = 0.042). Whilst the patients that underwent 
multimodal or surgery only had comparable pathological 
Univariate Multivariate
HR 95%CI P  value HR 95%CI P  value
  Patient factors
     Age 0.972 (0.944-1.00)   0.054
     Sex Female 1.000 Ref
Male 0.953 (0.453-2.005)   0.899
     ASA 1 1.000 Ref
2 0.696 (0.313-1.548)   0.374
3 0.947 (0.352-2.546)   0.914
     Performance status 0 1.000 Ref
1 1.016 (0.578-1.789)   0.955
2 0.950 (0.218-4.129)   0.945
  O-POSSUM
  Tumour response
     TRG 1 1.000 Ref
2 1.099 (0.099-12.148)   0.939
3 8.404 (1.071-65.929)   0.043
4 7.829 (1.054-58.163)   0.044
5         15.422   (2.083-114.189)   0.007
     TRG grouped 1-2 1.000 Ref 1.000 Ref
3-5 9.504 (2.973-30.380) < 0.0001 6.315 (1.261-31.616) 0.025
  Lymph node response
     Lymph nodes downstaged Yes 1.000 Ref 1.000 Ref
No 5.784 (3.064-10.919) < 0.0001 6.161 (1.683-22.554) 0.006
  Tumour factors
     ypT stage 0 1.000 Ref 1.000 Ref
1 2.085 (0.232-18.711)   0.512 0.281 (0.020-3.928) 0.345
2 5.214 (0.687-39.549)   0.110 0.286 (0.022-3.705) 0.338
3 9.490 (1.293-69.635)   0.027 0.469 (0.034-6.460) 0.571
4         52.907   (6.008-465.873) < 0.0001 1.519   (0.087-26.389) 0.774
     ypN stage 0 1.000 Ref 1.000 Ref
1 4.791 (2.434-9.431) < 0.0001 0.476 (0.133-1.700) 0.253
2 4.102 (2.005-8.392) < 0.0001 0.254 0.070-0.927) 0.038
3 7.449   (3.522-15.756) < 0.0001 0.476 (0.129-1.755) 0.265
     ypM stage 0 1.000 Ref 1.000 Ref
1 3.172 (1.253-8.031)   0.015 2.693 (0.924-7.847) 0.069
     Vascular invasion No 1.000 Ref 1.000 Ref
Yes 3.444 (2.080-5.702) < 0.0001 1.929 (1.034-3.600) 0.039
     Lymphatic invasion No 1.000 Ref 1.000 Ref
Yes 2.201 (1.268-3.821)   0.005 1.253 (0.637-2.462) 0.514
     Perineural invasion No 1.000 Ref 1.000 Ref
Yes 5.073 (2.896-8.886) < 0.0001 2.766 (1.444-5.300) 0.002
     Resection clearance R0 1.000 Ref 1.000 Ref
R1 3.869 (2.272-6.588) < 0.0001 1.805 (0.940-3.468) 0.076
Table 4  Univariate and multivariate Cox regression analyses of patient and tumour factors with disease free survival for patients 
undergoing neoadjuvant chemotherapy (n  = 136) 
TRG: Tumour Regression Grade; ASA: American Society of Anesthesiologists classification; O-POSSUM: Oesophagogastric surgery-physiological and 
operative severity score for the enumeration of mortality and morbidity. 
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staged disease they are different based on their clinical 
stage and survival. It is therefore unlikely that our clini-
cal staging was inadequate and suggests that the majority 
of  patients with ypN0 disease in fact had lymph node 
metastases prior to treatment. 
The increased survival observed with lymph node 
Noble F et al . Evaluating neoadjuvant chemotherapy in esophageal adenocarcinoma
pN0 Surgery alone 40 (35.4) ypN0 Neoadjuvant chemotherapy 
and surgery 73 (64.6)
P  value
  Preoperative status
  Age (range) yr1            73.62 (56.73-85.41)           65.59 (32.77-78.43) < 0.0001
  Sex ratio (M:F)1                  31 (77.5):9 (22.5)                66 (90.4):7 (9.8)  0.061
     cT stage 1    13 (32.5) 0 (0) < 0.0001
2    17 (42.5)      9 (12.3)
3 10 (25)    61 (83.6)
4 0 (0)    3 (4.1)
     cN stage 0    27 (67.5)    13 (17.8) < 0.0001
1    13 (32.5)    60 (82.2)
     cM stage 0   40 (100)    71 (97.3)  0.293
1 0 (0)    2 (2.8)
     Performance status 0    3 (9.4)    16 (21.9)  0.045
1    25 (78.1) 54 (74)
2      4 (12.5) 3 (4.1)
     ASA 1 2 (5)    6 (8.2)  0.268
2    31 (77.5)    59 (80.8)
3      7 (17.5)   8 (11)
  O-POSSUM1      17 (14-29)      16 (12-26)  0.015
     Tumour site Middle 1/3 0 (0)    1 (1.4)  0.190
Lower 1/3    15 (37.5)    35 (47.9)
OGJ-S1    11 (27.5)    12 (16.4)
OGJ-S2   8 (20)    16 (21.9)
OGJ-S3   6 (15)      9 (12.3)
  Operative outcomes
  Length of operation (min)1        240 (120-360)        278 (120-471)  0.082
  Blood loss (mL)1      200 (0-2200)      350 (0-3000)  0.167
     Clavien Dindo Max 0 14 (35)    24 (32.9)  0.709
1    1 (2.5)    3 (4.1)
2    17 (42.5) 27 (37)
3   4 (10)    10 (13.7)
4 2 (5)      9 (12.3)
5 2 (5) 0 (0)
  Anastomotic leaks   4 (10)    7 (9.6)   0.944
  Pathological outcomes
  TRG 1-2 -    34 (46.6) NA
  TRG 3-5 -    39 (53.4)
     pT or ypT 0 2 (5)    11 (15.1)  0.224
1 22 (55)    20 (27.4)
2      5 (12.5)    20 (27.4)
3 10 (25)    24 (32.9)
4 0 (0)    1 (1.4)
  Nodal Downstaged (cN1 to p or ypN0)    15 (37.5)    61 (83.6) < 0.0001
  Nodal yield1    16 (4-49)    18 (3-52)  0.150
     Resection clearance R0    35 (87.5)    69 (94.5)  0.189
  Vascular invasion      7 (17.5)    10 (13.7)  0.590
  Lymphatic invasion 2 (5)    6 (8.2)  0.525
  Perineural invasion 2 (5)    5 (6.8)  0.698
  Maximum tumour diameter (mm)1    24 (0-50)      24 (0-110)  0.324
     Morphology Ulcer    25 (65.8)    53 (79.1)  0.135
Polypoid    10 (26.3)    11 (16.4)
Fungating    1 (2.6)    1 (1.5)
Diffuse infiltrating    2 (5.3) 2 (3)
     Grade G1   4 (10)    13 (17.8)  0.811
G2    17 (42.5)    20 (27.4)
G3    19 (47.5)    40 (54.8)
G4 0 (0) 0 (0)
     Site of recurrence Local 0 (0)    2 (2.7)  0.293
Nodal    1 (2.5)    4 (5.5)  0.463
Distant    3 (7.5)    12 (16.4)  0.182
Table 5  Clinical and pathological characteristics of the 113 patients with pathological N0 stage, according to treatment  n  (%)
Values in parentheses are percentages unless indicated. 1Values in parentheses are range. ASA: American society of anesthesiologists classification; 
O-POSSUM: Oesophagogastric surgery-physiological and operative severity score for the enumeration of mortality and morbidity; NA: Not available. 
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downstaging has important implications for the stag-
ing of  OAC as neoadjuvant therapy is increasingly used. 
Although the final pathological stage of  disease may be 
similar between patients treated with either multimodal 
therapy or surgery alone we have demonstrated that 
the long-term DFS of  these patients are different. This 
would suggest revisions for the staging system for OAC 
to take into account the differences in outcomes for pa-
tients who have similar pathologically staged disease after 
multimodal therapy compared to those treated by surgery 
alone. This hypothesis is further supported by the results 
of  our multivariate analysis of  factors independently re-
lated to outcome in neoadjuvant chemotherapy for OAC. 
This showed that nodal downstaging and TRG were in-
dependent predictors of  DFS but that the classical mark-
ers of  disease burden, PT stage and PN stage, were only 
statistically significant on univariate analysis. Similar ob-
servations and suggestions have been made for patients 
who have undergone neoadjuvant chemoradiotherapy 
followed by surgery when compared to patients who un-
derwent surgery alone[31]. 
There are several advantages of  our study compared 
to other published series. This study consists of  a large 
number of  consecutive patients (n = 218) of  uniform 
histological type, with consistent clinical and pathological 
staging and treatment provided over a contemporary time 
period. The retrospective nature of  this study and the use 
of  multiple pathologists assessing TRG on an individual 
basis are potential limitations. However, the data was vig-
orously collected prospectively and the use of  multiple 
pathologists reflects the usefulness of  TRG in clinical 
practice and is pragmatic. A debate also remains as to 
what system to use to assess a local tumour response to 
neoadjuvant therapy[10,11,14,15,17-19]. The use of  TRG is not 
without controversy as significant tumour regression has 
been reported in patients who underwent surgery alone, 
in up to 13.7% of  cases. It has been suggested that this 
reflects tumour growth within abundant stroma and/or 
lymphocytic infiltration leading to partial tumour regres-
sion[21]. While the association of  lymphocytic infiltration 
and stromal features with survival in cancer is not new 
their association with survival in OAC is yet to be fully 
understood and the clinical impact is unknown[32].
Although a good pathological response of  the pri-
mary tumour might be expected to represent a prognos-
tic predictor after NAC, the low response rate observed 
following NAC remains problematic. In this study we ob-
served a significant response rate of  26.5% (n = 36) as as-
sessed by TRG. However when lymph node downstaging 
is also considered this proportion increases to 48.5% (n = 
66). It can be hypothesised that patients who have a par-
tial response to NAC reflected by downstaging of  lymph 
nodes with modest or no response in the primary tumour 
(TRG 3-5) may be the most appropriate to be considered 
for trials of  adjuvant treatment; as there is limited data 
from other disease sites to suggest only patients respond-
ing to neoadjuvant treatment benefit from further treat-
ment[33]. This is relevant as the role of  adjuvant therapy 
in esophageal cancer is controversial due to concerns 
over the additional benefit of  post operative treatment 
over neoadjuvant alone[8] and toxicity[34], and has resulted 
in the lack of  adoption in the United Kingdom[1]. What 
is clear is that the group of  patients with no significant 
downstaging and ypN1 post neoadjuvant treatment have 
a particularly poor outlook. This group urgently requires 
identification at diagnosis and new trial treatments. This 
requires the ongoing studies of  prognostic and predictive 
biomarkers from this cohort and others to yield meaning-
ful and validated results.
One can now begin to consider an evolving algorithm 
for perioperative treatment of  OAC that may involve 
induction chemotherapy followed by an early assessment 
of  response and the curtailment of, or a change of, neo-
adjuvant therapy for non-responders. Further analysis of  
the primary tumour and lymph nodes after surgery would 
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Figure 3  Kaplan-Meier curves of patients undergoing multimodal therapy 
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LN: Lymph node.
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direct patients with modest or no tumour response (TRG 
3-5) to NAC, but with nodal downstaging, to adjuvant 
therapy. This kind of  stratified therapy will be supported 
by ongoing studies of  biomarkers and molecular imaging. 
The contribution of  the tumour microenvironment is 
also likely to offer new targets for therapy and may be the 
place to look to explain the different responses to therapy 
observed between otherwise similar tumours.
In summary, this study has shown that a response to 
NAC in the primary tumour and in the lymph nodes is as-
sociated with improved outcomes after surgery for adeno-
carcinoma of  the esophageal and gastro-esophageal. A pre-
viously unidentified group of  patients who appear to have 
a poor tumoural response to NAC (TRG 3-5) do benefit 
from NAC with nodal downstaging and increased DFS.
We propose that methods to assess the pathological 
response to NAC are refined so that both the response 
in the primary tumour and the regional lymph nodes is 
used to guide selection of  tailored post operative treat-
ment strategies, identify biomarkers of  response to che-
motherapy, provide prognostic information and assess 
multimodal therapies. 
COMMENTS
Background
Adenocarcinoma of the esophagus and esophageal adenocarcinoma (OAC) is 
a significant and increasing health problem in many countries; linked to rates of 
obesity, smoking, gastro-esophageal reflux disease and Barrett’s oesophagus. 
At presentation, even in operable cases, tumours are often locally advanced 
(T3N1) with multi-institutional randomised studies of surgery alone giving 5 
years survival rates in the order of 15%-24%. So as well as a focus on earlier 
detection and screening of at risk groups, clinical research has focused on ad-
juvant and specifically neo-adjuvant treatments prior to resection. 
Research frontiers
Neoadjuvant chemotherapy can be considered one standard of care, with a 
modest improvement in outcome over surgery alone; detailed in a recent meta-
analysis as HR = 0.83 (95%CI: 0.71-0.95), or an absolute benefit of 5%-10% 
at 2 years. A key focus now is on identifying optimum neoadjuvant approaches 
(which chemotherapy regimens, chemoradiotherapy, small molecule inhibitors, 
biologic agents etc) and which patients should receive them e.g., patients with 
human epidermal growth factor receptor (HER)-2 over expressing tumours re-
ceiving a Trastuzumab containing regimen.
Innovations and breakthroughs
To date prognostic information for OAC has been from standard clinicopathologi-
cal data, and bar HER-2 expression predictive markers of response to treatment 
are lacking. The authors cannot predict at diagnosis who is going to gain from 
neoadjuvant treatment. Globally collaborative groups have been set up to gener-
ate large clinical datasets to link patient outcomes to molecular features: groups 
such as the oesophageal cancer clinical and molecular stratification study group 
in the United Kingdom, which are beginning to highlight important molecular 
determinants of OAC behaviour and identify attractive targets for therapy. The 
expectation is this will lead to valuable prognostic information and also identify 
who should, and should not proceed to a particular neoadjuvant strategy.
Applications
The identification here that both T and N downstaging post neoadjuvant treat-
ment need to be accounted for will help refine clinical datasets and provide prog-
nostic information, as well as inform decisions concerning adjuvant treatment.
Terminology
When reporting the anatomical extent of cancer after preoperative treatment 
has been given pathologists include the prefix “y” to the PTNM.
Peer review
This study is an excellent clinical research as it confirms the association 
between regression grade and prognosis in a large and histologically homog-
enous group of patients treated with platinum based triplet chemotherapy and 
staged uniformly. It contains novel findings that are clinically relevant to physi-
cians treating oesophageal cancer and assessment of both T and N responses 
to neoadjuvant therapy may be of relevance and interest to specialists treating 
other solid tumours.
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